MN
MNKD.US MannKind Corp
- Market cap
- USD 1.33B
- P/E
- -
- P/B
- 187.85x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MNKD.US undervalued?
Graham numberThe Graham number of MannKind Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MannKind Corp fundamental analysis
No fundamental analysis for MannKind Corp yet.
MannKind Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation…
Full company profileMannKind Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MannKind Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 175M | 11.7M | 27.9M | 63.0M | 65.1M | 75.4M | 99.8M | 199M | 286M | 349M | 402M |
| Gross Profit | 125M | -5.48M | 7.38M | 35.1M | 40.5M | 36.6M | 42.3M | 136M | 209M | 288M | 302M |
| Operating Income | 67.3M | -108M | -76.6M | -44.6M | -47.9M | -47.0M | -64.1M | 8.68M | 72.6M | 38.8M | -7.36M |
| EBITDA | 64.6M | -100M | -75.6M | -38.8M | -44.7M | -61.1M | -56.3M | 16.4M | 77.5M | 27.5M | 14.0M |
| Net Income | 126M | -117M | -87.0M | -51.9M | -57.2M | -80.9M | -87.4M | -11.9M | 27.6M | 5.86M | -78.5M |
| EPS | 1.36 | -1.13 | -0.60 | -0.27 | -0.26 | -0.32 | -0.34 | -0.04 | 0.10 | 0.02 | -0.25 |
| Balance Sheet | |||||||||||
| Total Assets | 107M | 84.6M | 108M | 93.7M | 109M | 321M | 295M | 475M | 394M | 792M | 723M |
| Total Liabilities | 291M | 299M | 283M | 284M | 289M | 531M | 546M | 721M | 473M | 843M | 760M |
| Shareholders' Equity | -184M | -215M | -175M | -191M | -180M | -209M | -251M | -246M | -78.8M | -51.0M | -37.3M |
| Cash & Short-term Investments | 22.9M | 43.9M | 71.2M | 49.9M | 67.0M | 204M | 171M | 295M | 197M | 171M | 96.6M |
| Total Debt | 148M | 157M | 102M | 121M | 123M | 289M | 288M | 273M | 47.7M | 473M | 434M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -78.1M | -64.8M | -37.7M | -88.5M | -28.1M | -61.7M | -80.7M | 34.1M | 42.5M | 18.3M | -78.1M |
| Capital Expenditure | 1.14M | 1.14M | 354K | 2.57M | 4.78M | 11.5M | 7.59M | 42.4M | 9.69M | 4.57M | 13.6M |
| Free Cash Flow | -79.2M | -65.9M | -38.1M | -91.0M | -32.9M | -73.2M | -88.3M | -8.35M | 32.8M | 13.7M | -91.6M |
| Ratios | |||||||||||
| ROA | 117.4% | -138.7% | -80.8% | -55.4% | -52.7% | -25.2% | -29.6% | -2.5% | 7.0% | 0.7% | -10.9% |
| Net Profit Margin | 71.9% | -999.0% | -312.2% | -82.3% | -87.9% | -107.3% | -87.6% | -6.0% | 9.7% | 1.7% | -19.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MannKind Corp dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 498K | 0.00 | - |
| 2020 | USD 14.9M | 0.07 | - |
| 2019 | USD 656K | 0.00 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:5 on Mar 3, 2017.
Who owns MannKind Corp
- Insiders 2.08%
- Institutions 56.56%
- Public & others 41.37%
- Shares outstanding 322M
- Free float 298M
Top funds holding MNKD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 10.2M | 3.18% | +9.51% | Sep 2026 |
| iShares Russell 2000 ETF | 7.97M | 2.48% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 7.69M | 2.39% | +2.69% | Oct 2026 |
| Fidelity Select Biotechnology | 4.52M | 1.41% | +1.05% | Aug 2026 |
| Fidelity Small Cap Index | 3.37M | 1.05% | +0.18% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 2.98M | 0.93% | -0.38% | Oct 2026 |
| iShares Biotechnology ETF | 2.39M | 0.74% | -0.19% | Oct 2026 |
| Vanguard Russell 2000 ETF | 1.85M | 0.58% | +4.71% | Sep 2026 |
| First Trust Small Cap Gr AlphaDEX® ETF | 1.76M | 0.55% | +0.43% | Oct 2026 |
| Schwab US Small-Cap ETF™ | 1.71M | 0.53% | +0.24% | Oct 2026 |
| BlackRock Advantage Small Cap Core Instl | 1.54M | 0.48% | +0.13% | Sep 2026 |
| Fidelity Extended Market Index | 1.52M | 0.47% | -0.38% | Sep 2026 |
| Vanguard Health Care ETF | 890K | 0.28% | -0.09% | Sep 2026 |
| Janus Henderson Small/Md Cp Gr Alpha ETF | 803K | 0.25% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 773K | 0.24% | +3.33% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 593K | 0.18% | +3.07% | Sep 2026 |
| Fidelity Total Market Index | 580K | 0.18% | -0.05% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 519K | 0.16% | -5.90% | Oct 2026 |
| Fidelity Series Total Market Index | 478K | 0.15% | 0.00% | Sep 2026 |
| iShares Core S&P Total US Stock Mkt ETF | 467K | 0.15% | +0.03% | Oct 2026 |
Top institutions holding MNKD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 32.1M | 9.99% | +12.35% | Jun 2026 |
| Rubric Capital Management LP | 18.0M | 5.60% | +397.18% | Jun 2026 |
| State Street Corp | 16.2M | 5.03% | -13.43% | Jun 2026 |
| Vanguard Capital Management, LLC | 13.2M | 4.09% | +2.16% | Jun 2026 |
| Geode Capital Management, LLC | 7.95M | 2.47% | +5.89% | Jun 2026 |
| Wellington Management Company LLP | 7.84M | 2.44% | +138.94% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 6.60M | 2.05% | +11.86% | Jun 2026 |
| Deep Track Capital, LP | 6.00M | 1.87% | 0.00% | Jun 2026 |
| 180 WEALTH ADVISORS, LLC | 4.96M | 1.54% | +15.56% | Jun 2026 |
| TSP Capital Management Group/LLC | 4.18M | 1.30% | +5.23% | Sep 2026 |
| FMR Inc | 4.10M | 1.28% | +17.81% | Jun 2026 |
| AQR Capital Management LLC | 3.81M | 1.18% | +740.83% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.47M | 1.08% | -40.02% | Jun 2026 |
| BRAIDWELL LP | 3.46M | 1.08% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.00M | 0.93% | -5.35% | Jun 2026 |
| Northern Trust Corp | 2.89M | 0.90% | +7.90% | Jun 2026 |
| UBS Group AG | 2.89M | 0.90% | -65.04% | Jun 2026 |
| Two Sigma Investments LLC | 2.69M | 0.84% | -6.98% | Jun 2026 |
| Charles Schwab Investment Management Inc | 2.60M | 0.81% | +1.95% | Jun 2026 |
| Bank of America Corp | 2.36M | 0.74% | -30.11% | Jun 2026 |
MannKind Corp company profile
- Company name
- MannKind Corp
- Ticker
- MNKD.US
- Exchange
- USA Stocks
- Listed since
- Jul 28, 2004
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 591
- Fiscal year end
- December
- Address
- 1 Casper Street, Danbury, CT, United States, 06810
- Phone
- 818 661 5000
- Website
- mannkindcorp.com
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company's commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin. It also developed Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension, as well as for the treatment of pulmonary hypertension associated with interstitial lung disease. The company's pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701 that focuses on bumetanide. It has collaboration and license agreement with United Therapeutics Corporation; collaboration agreement with Thirona Bio, Inc. to evaluate the therapeutic for the treatment of pulmonary fibrosis; and licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere for weight management. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
MannKind Corp management
8- Dr. Michael E. Castagna Pharm.D.CEO & Director · born 1976
- Mr. Christopher B. Prentiss M.B.A.Chief Financial Officer · born 1975
- Dr. David B. Thomson J.D., Ph.D.Executive VP, General Counsel & Secretary · born 1967
- Dr. Stuart A. Tross Ph.D.Chief People & Workplace Officer · born 1967
- Mr. Dominic Marasco R.Ph.President of Endocrine Business Unit · born 1972
- Mr. Sanjay Singh M.B.A.Executive Vice President of Technical Operations · born 1966
- Dr. Ajay Ahuja M.B.A., M.D.Executive VP & Chief Medical Officer · born 1970
- Dr. Wassim Fares M.D., M.Sc.Senior VP and Therapeutic Area Head of Respiratory & (interim) Cariorenal